Epigenomics AG
Andreas Aurenz currently serves as a Technischer Angestellter at Umweltbundesamt - German Environment Agency since March 2024. Prior to this role, Andreas Aurenz has been with Epigenomics AG as a Senior Technician since September 2001, focusing on development. Earlier experience includes working as a BTA at the Robert Koch Institute from July 2000 to August 2001, where responsibilities involved cell culture in xenotransplantation, and at Charité from June 1998 to June 2000, contributing to urological research. Education was attained at Oberstufenzentrum Chemie, Biologie, Physik from 1995 to 1998.
This person is not in any teams
This person is not in any offices
Epigenomics AG
Epigenomics is a molecular diagnostics company focused on the development of blood-based DNA methylation tests for the early the detection of cancer. The Epi proColon test has recently become the first and only FDA approved blood test for colorectal cancer screening. Epi proColon, HCCBloodTest, and the Epi proLung tests are available in Europe as CE-marked IVDs. Industry partners, as well as the medical and life science communities, can access our expansive intellectual property portfolio. Epigenomics has been granted over 60 patents, in addition to many others that have been filed. These patents cover DNA methylation technologies and biomarkers, as well as our DNA methylation expertise through research products, biomarker services, IVD development collaborations, and licensing.